Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Roche’s Tecentriq gets CHMP recommendation as adjuvant treatment for early NSCLC
The drug will be indicated as an adjuvant treatment for NSCLC in adults with a high risk of recurrence with PD-L1≥50% and without EGFR mutant or ALK-positive NSCLC,
The drug will be indicated as an adjuvant treatment for NSCLC in adults with a high risk of recurrence with PD-L1≥50% and without EGFR mutant or ALK-positive NSCLC,
Although HCC is the most common type of liver cancer, options to treat the disease are restricted. The total prognosis for survival is poor, with a five-year survival
BenevolentAI is clinical-stage artificial intelligence (AI) enabled drug discovery company, while DNDi) is a not-for-profit research and development (R&D) organisation with focus on neglected diseases., The company focuses
Located in Frederick, Maryland, the 275,000ft2 facility will produce the FDA-approved CAR T-cell therapy which is utilised for the treatment of blood cancer. The CAR T-cell therapies are
As part of the collaboration, the companies will jointly develop new antibody drugs which can significantly expand the immunotherapy’s potential in improving the lives of cancer and other
Bionova Scientific is a portfolio company of private investment firm Great Point Partners. It offers contract process development services as well as GMP-compliant contract manufacturing services to biopharmaceutical
The drug is claimed to be the first and only oral MET inhibitor recommended to treat advanced NSCLC harbouring mesenchymal-epithelial transition factor gene (MET) exon 14 (METex14) skipping
Padcev is indicated as a monotherapy to treat locally advanced or metastatic urothelial cancer adult patients who previously received a platinum-containing chemotherapy and a PD-1/L1 inhibitor. The regulatory
Led by Deerfield Management, the funding round saw participation from existing investors Petrichor Healthcare Capital Management, Flying L Partners, Falcon Vision, an ophthalmology-focused investment platform backed by KKR,
Initially executed in 2017, the agreement grants exclusive rights to Kyowa Kirin for the development and commercialisation of Ardelyx’s tenapanor to treat cardiorenal diseases including hyperphosphatemia in Japan.